Literature DB >> 9314428

Effects of blood pressure control on progressive renal disease in blacks and whites. Modification of Diet in Renal Disease Study Group.

L A Hebert1, J W Kusek, T Greene, L Y Agodoa, C A Jones, A S Levey, J A Breyer, P Faubert, H A Rolin, S R Wang.   

Abstract

African Americans (blacks) have a disproportionately high incidence of end-stage renal disease due to hypertension. The Modification of Diet in Renal Disease (MDRD) Study found that strict blood pressure control slowed the decline in glomerular filtration rate (GFR) only in the subgroup of patients with proteinuria. The present report compares the effects of blood pressure control in black and white MDRD Study participants. Fifty-three black and 495 white participants with baseline GFRs of 25 to 55 mL/min/1.73 m2 were randomly assigned to a usual or low mean arterial pressure (MAP) goal of < or = 107 or < or = 92 mm Hg, respectively. GFR decline was compared between randomized groups and correlated with the level of achieved blood pressure. The mean (+/-SE) GFR decline over 3 years in the low blood pressure group was 11.8+/-7.3 mL/min slower than in the usual blood pressure group among blacks (P=.11) compared with 0.3+/-1.3 mL/min slower among whites (P=.81) (P=.12 between blacks and whites). In both blacks and whites, higher baseline urine protein excretion was associated with a greater beneficial effect of the low MAP goal on GFR decline (P=.02 for both races). Combining both blood pressure groups and controlling for baseline characteristics, higher follow-up achieved MAP was associated with faster GFR decline in both blacks (P<.001) and whites (P=.002), with a sevenfold stronger relationship in blacks (P<.001). These secondary analyses support the prior recommendation for a lower than usual blood pressure goal (MAP < or = 92 mm Hg) in black and white patients with proteinuria (> 1 g/d). In addition, a lower level of blood pressure control may be even more important in blacks than in whites in slowing the progression of renal disease.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9314428     DOI: 10.1161/01.hyp.30.3.428

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  39 in total

Review 1.  Preventing renal disease progression: is it the drug or the blood pressure reduction, or both?

Authors:  M R Weir
Journal:  Curr Hypertens Rep       Date:  2000-12       Impact factor: 5.369

2.  Oral supplement of six selective amino acids arrest progression renal failure in uremic patients.

Authors:  Hippocrates Yatzidis
Journal:  Int Urol Nephrol       Date:  2004       Impact factor: 2.370

Review 3.  Position statement on use of pharmacological combinations in a single pill for treatment of hypertension by Argentine Federation of Cardiology (FAC) and Argentine Society of Hypertension (SAHA).

Authors:  Nicolás Renna; Daniel Piskorz; Diego Stisman; Diego Martinez; Ludmila Lescano; Sergio Vissani; Walter Espeche; Diego Marquez; Roberto Parodi; Diego Naninni; Marcos Baroni; Daniel Llanos; Rocio Martinez; Jessica Barochinner; Gustavo Staffieri; Fernando Lanas; Mónica Velásquez; Marcos Marin; Bryan Williams; Irene Ennis
Journal:  J Hum Hypertens       Date:  2021-06-04       Impact factor: 3.012

Review 4.  Rationale for fixed-dose combinations in the treatment of hypertension: the cycle repeats.

Authors:  Domenic A Sica
Journal:  Drugs       Date:  2002       Impact factor: 9.546

Review 5.  Choices and goals in the treatment of the diabetic hypertensive patient.

Authors:  E Basta; G Bakris
Journal:  Curr Hypertens Rep       Date:  2001-10       Impact factor: 5.369

Review 6.  Renal protection and antihypertensive drugs: current status.

Authors:  A Salvetti; P Mattei; I Sudano
Journal:  Drugs       Date:  1999-05       Impact factor: 9.546

Review 7.  What Are Optimal Blood Pressure Targets for Patients with Hypertension and Chronic Kidney Disease?

Authors:  Gopesh K Modi; Rajiv Agarwal
Journal:  Curr Cardiol Rep       Date:  2015-11       Impact factor: 2.931

Review 8.  New insights on the risk for cardiovascular disease in African Americans: the role of added sugars.

Authors:  Karim R Saab; Jessica Kendrick; Joseph M Yracheta; Miguel A Lanaspa; Maisha Pollard; Richard J Johnson
Journal:  J Am Soc Nephrol       Date:  2014-08-04       Impact factor: 10.121

9.  Medication Utilization Patterns and Hypertension-Related Expenditures among Patients Who Were Switched from Fixed-Dose To Free-Combination Antihypertensive Therapy.

Authors:  Gregory Hess; Jerrold Hill; Helen Lau; Homa Dastani; Paresh Chaudhari
Journal:  P T       Date:  2008-11

10.  High perfusion pressure accelerates renal injury in salt-sensitive hypertension.

Authors:  Takefumi Mori; Aaron Polichnowski; Padden Glocka; Mary Kaldunski; Yusuke Ohsaki; Mingyu Liang; Allen W Cowley
Journal:  J Am Soc Nephrol       Date:  2008-04-16       Impact factor: 10.121

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.